DICE Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (8 aug 2023 @ 22:00):

DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas...

Stats
Dagens volum	4.33M
Gjennomsnittsvolum	1.75M
Markedsverdi	2.27B
EPS	$0 ( 2024-03-14 )
Neste inntjeningsdato	( $0 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-21.91
ATR14	$0.513 (1.08%)

Insider Trading

Date	Person	Action	Amount	type
2023-08-09	Ra Capital Management, L.p.	Sell	786 407	Common Stock
2023-08-09	Ra Capital Management, L.p.	Sell	21 250	Stock Option (Right to Buy)
2023-08-09	Tetlow Sharon	Sell	49 841	Common Stock
2023-08-09	Tetlow Sharon	Sell	13 800	Stock Option (right to buy)
2023-08-09	Tetlow Sharon	Sell	21 250	Stock Option (right to buy)

INSIDER POWER
-56.57
Last 99 transactions
Buy: 13 025 781 \| Sell: 10 716 392

Volum Korrelasjon

Lang: 0.25 (neutral)

Kort: 0.00 (neutral)

Signal:(77.583) Neutral

DICE Therapeutics, Inc. Korrelasjon

10 Mest positive korrelasjoner
MRNS	0.883
DGNU	0.879
ABCM	0.863
ABEO	0.86
SKYW	0.86
SINO	0.859
FSFG	0.858
CGNT	0.858
DFH	0.855
IRBT	0.851

10 Mest negative korrelasjoner
WYNN	-0.869
MCFT	-0.869
LIBY	-0.867
LSCC	-0.866
ASUR	-0.865
TGLS	-0.864
ULTA	-0.863
KYCH	-0.863
ARYD	-0.863
LAKE	-0.863

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

DICE Therapeutics, Inc. Korrelasjon - Valuta/Råvare

0.91
( very strong )

-0.70
( moderate negative )

0.79
( moderate )

0.18
( neutral )

-0.51
( weak negative )

DICE Therapeutics, Inc. Økonomi

Annual	2022
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$-2.07

FY	2022
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$-2.07

FY	2021
Omsetning:	$1.13M
Bruttogevinst:	$1.13M (100.00 %)
EPS:	$-2.11

FY	2020
Omsetning:	$863 000
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-1.020

Financial Reports:

No articles found.

DICE Therapeutics, Inc.

DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17, which is a validated drug target implicated in a various immunology indications. It is also developing oral therapeutic candidates targeting a4ß7 integrin for the treatment of inflammatory bowel diseases, as well as targeting aVß1/aVß6 integrin for the treatment of idiopathic pulmonary fibrosis. In addition, the company focuses on immuno-oncology for antibody therapeutics. The company was incorporated in 2013 and is headquartered in South San Francisco, California.